scholarly journals A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours

Oncotarget ◽  
2014 ◽  
Vol 5 (22) ◽  
pp. 11154-11167 ◽  
Author(s):  
David S. Hong ◽  
Razelle Kurzrock ◽  
Marilyn Mulay ◽  
Erik Rasmussen ◽  
Benjamin M. Wu ◽  
...  
Keyword(s):  
Solid Tumours ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Phase 1B

scholarly journals Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment

2019 ◽  
Vol 85 (6) ◽  
pp. 1239-1246 ◽  
Author(s):  
Muhammad Wasif Saif ◽  
Lee Rosen ◽  
Michelle A. Rudek ◽  
Weijing Sun ◽  
Dale R. Shepard ◽  
...  
Keyword(s):  
Hepatic Impairment ◽  
Solid Tumours ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2

2018 ◽  
Vol 118 (3) ◽  
pp. 344-352 ◽  
Author(s):  
Rastislav Bahleda ◽  
Andrea Varga ◽  
Yann Bergé ◽  
Jean-Charles Soria ◽  
David Schnell ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumours ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

2018 ◽  
Vol 93 (5) ◽  
pp. 607-614 ◽  
Author(s):  
Carlo Gambacorti-Passerini ◽  
Sergey Orlov ◽  
Li Zhang ◽  
Fadi Braiteh ◽  
Huiqiang Huang ◽  
...  
Keyword(s):  
Long Term Effects ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Phase 1B ◽  
Alk Positive

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

2011 ◽  
Vol 30 (5) ◽  
pp. 1962-1971 ◽  
Author(s):  
Tanja Trarbach ◽  
Beate Schultheis ◽  
Thomas C. Gauler ◽  
Vesile Schneider ◽  
Dirk Strumberg ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumours ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Src Inhibitor ◽  
Vegf Signalling

scholarly journals A phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumours (NCT03447314)

2019 ◽  
Vol 30 ◽  
pp. v192-v193
Author(s):  
A.R. Hansen ◽  
J. Strauss ◽  
J. Chaves ◽  
S.A. Piha-Paul ◽  
H. Park ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumours ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document